E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Healty volunteers: active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive infections caused by Haemophilus influenzae type b (such as meningitis, septicaemia, cellulitis, arthritis, epiglottitis, pneumopathy, osteomyelitis). |
|
E.1.1.1 | Medical condition in easily understood language |
Protection against diphtheria, tetanus, pertussis, poliomyelitis and
invasive infections caused by Haemophilus influenzae type b. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10036897 |
E.1.2 | Term | Prophylactic vaccination |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | HLGT |
E.1.2 | Classification code | 10043413 |
E.1.2 | Term | Therapeutic procedures and supportive care NEC |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10021430 |
E.1.2 | Term | Immunisation |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10021431 |
E.1.2 | Term | Immunisations |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Immunogenicity:
To assess the seroprotection rates (D, T, polio types 1, 2 and 3, and PRP) and seroconversion rates (PT, FHA) of Aventis Pasteur's DTacP-IPV//PRP~T combined vaccine, one month after the three-dose primary vaccination.
To describe the immunogenicity of the study combined vaccine (PENTAXIM™) one month after the three-dose primary vaccination (Visit 5), prior to the booster dose (at Visit 6) and one month after the booster dose (Visit 7).
To describe the immunogenicity of the recombinant hepatitis B vaccine antigen one
month after the three-dose primary vaccination (Visit 5) and approximately 14 to 15
months later (Visit 6).
Safety:
• To describe the safety after each dose of the study combined vaccine (PENTAXIM™).
• To describe the safety after each dose of recombinant hepatitis B vaccine. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) At Visit 01 (screening)
1) Aged < 24 hours on the day of inclusion
2) Born at full term pregnancy (>37 weeks) with a birth weight ≥ 2.5 kg
3) Informed consent form signed by the parent(s) or other legal representative
4) Able to attend all scheduled visits and to comply with all trial procedures |
|
E.4 | Principal exclusion criteria |
At visit 01( screening):
1) Illness at a stage that could interfere with trial conduct or completion.
2) Any vaccination preceding the trial participation (except BCG)
3) Acute illness on the day of screening.
At visit 01 and visit 02 (screening & first study vaccination):
4) Planned participation in another clinical trial during the present trial period
5) Blood or blood–derived products received since birth.
6) Mother known as seropositive to HIV or Hepatitis B.
7) Known thrombocytopenia or a bleeding disorder contraindicating intramuscular
vaccination
8) History of/current seizures
At visit 02 (first study vaccination):
9) Participation in another clinical trial preceding the first trial vaccination
10) Congenital or acquired immunodeficiency, immunosuppressive therapy such as
long-term systemic corticosteroids therapy
11) Systemic hypersensitivity to any of the vaccine components or history of a lifethreatening
reaction to the trial vaccine or a vaccine containing the same substances
12) Chronic illness at a stage that could interfere with trial conduct or completion.
13) Any vaccination preceding the first trial vaccination (except BCG)
14) History of diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae
type b and hepatitis B infection (confirmed either clinically, serologically or
microbiologically).
15) Previous vaccination against the diphtheria, tetanus, pertussis, poliomyelitis
Haemophilus influenzae type b and hepatitis B infection with the trial vaccine or
another vaccine.
16) Febrile illness (rectal temperature ≥ 38.0°C or axillary temperature ≥ 37.4°C) or
acute illness on the day of first vaccination |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Immunogenicity:
One month after the third dose of study combined vaccine (visit 5)
- individual antibodies titers : all antibodies
-anti-Diphtheria antibody titers ≥ 0.01 IU/mL (ELISA)
- anti-Diphtheria antibody titers ≥ 0.1 IU/mL (ELISA)
- anti-Diphtheria antibody titers ≥ 0.01 IU/mL (Seroneutralization)
- anti-Diphtheria antibody titers ≥ 0.1 IU/mL (Seroneutralization)
- anti-Tetanus antibody titers ≥ 0.01 IU/mL (ELISA)
- anti-Tetanus antibody titers ≥ 0.1 IU/mL (ELISA)
-anti-Polio 1, 2 and 3 antibody titers ≥ 8 (1/dil) (Seroneutralization)
-anti-PRP antibody titer ≥ 0.15 μg/mL (Farr type RIA)
-anti-PRP antibody titers ≥ 1.0 μg/mL (Farr type RIA)
-anti-PT and anti-FHA antibody titers (EU/mL) ≥ 4-fold increase (ELISA)
-anti-PT and anti-FHA antibody titers (EU/mL) ≥ 2-fold increase (ELISA)
- anti-PT and anti-FHA antibody titers ≥ 5 EU/mL, ≥ 10 EU/mL and ≥ 25 EU/mL
(ELISA)
- anti-HBs antibody titers ≥ 10 mIU/mL (RIA)
- individual titers ratios*: for anti-FHA (EU/mL) and anti-PT (EU/mL) antibodies
(ELISA).
Before the booster dose of the study combined vaccine (Visit 6)
- individual antibody titers: anti-HBs antibodies (mIU/mL) (RIA)
- anti-HBs antibody titers ≥ 10 mIU/mL (RIA)
Before (visit 6) and after (visit 7) the booster dose of the study combined vaccine
- individual antibody titers: all antibodies (except anti-HBs antibodies)
- anti-PRP antibody titers ≥ 0.15 μg/mL and ≥ 1.0 μg/mL (Farr type RIA)
- anti-Diphtheria antibody titers ≥ 0.01 IU/mL and ≥ 0.1 IU/mL (ELISA and
Seroneutralisation)
- anti-Tetanus antibody titers ≥ 0.01 IU/mL and ≥ 0.1 IU/mL (ELISA)
- anti-Polio 1, 2 and 3 antibody titers ≥ 8 (1/dil) (Seroneutralization)
- anti-PT and anti-FHA antibody titers ≥ 5 EU/mL, ≥ 10 EU/mL and ≥ 25 EU/mL
(ELISA)
One month after the booster dose of the study combined vaccine (visit 7)
- anti-PT and anti-FHA antibody titers (EU/mL) ≥ 2- and 4-fold increase (ELISA)
- individual antibody titers ratio *: anti-FHA (EU/mL) and anti-PT (EU/mL) antibody
titers (ELISA).
*Individual titer ratio: post-primary vaccination / pre-primary vaccination and post-booster dose / prebooster dose
Safety:
The occurrence, time to onset, duration, severity, and seriousness of the solicited (terms pre-listed in the CRF) injection site and systemic reactions between D0 and D7 after each injection:
The occurrence, nature (MedDRA preferred term), time to onset, duration, severity, relationship to vaccination and seriousness of unsolicited (spontaneously reported) systemic adverse events from vaccination day to the next study visit.
The occurrence, nature (MedDRA preferred term), time to onset, duration, severity, and seriousness of unsolicited (spontaneously reported) injection site adverse events from vaccination day to the next study visit.
The occurrence, nature, time to onset, duration, severity, relationship to vaccination of any serious adverse event SAE occurring throughout the trial.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
A blood samples (BL) of 5 mL each will be taken:
• just before the first dose (BL01-Visit 2),
• one month after the third dose (BL02-Visit 5),
• just before the booster dose (BL03-Visit 6), and
• one month after the booster dose (BL04-Visit 7) of combined vaccine. |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
Will this trial be conducted at a single site globally?
| Yes |
E.8.4 | Will this trial be conducted at multiple sites globally? | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 8 |